DOCSLIB.ORG

Department of Medicine Annual Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

DEPARTMENT OF MEDICINE 2018 Annual Report DIVISIONS AND INSTITUTES The Divisions » Cardiology James Udelson, MD » Clinical Care Research Harry Selker, MD » Clinical Decision Making John Wong, MD » Clinical Nutrition Edward Saltzman, MD » Endocrinology, Diabetes and Metabolism Ron Lechan, MD » Gastroenterology Joel Weinstock, MD » Geographic Medicine and Infectious Diseases David Snydman, MD » Hematology/Oncology Rachel Buchsbaum, MD » Internal Medicine and Adult Primary Care Deborah Blazey-Martin, MD » Nephrology Andrew Levey, MD » Palliative Care Tamara Vesel, MD » Pulmonary, Critical Care and Sleep Medicine Nicholas Hill, MD » Rheumatology, Allergy and Immunology Timothy McAlindon, MD The Institutes » Institute for Clinical Research and Health Policy Studies Harry Selker, MD » Molecular Cardiology Research Institute Iris Jaffe, MD, PhD TABLE OF CONTENTS The Department of Medicine Chairman’s Message 4 Diversity and Inclusion Efforts 6 Departmental Leadership 8 Departmental Organization Chart 9 Clinical Activity 13 Research Activity 15 Internal Medicine Training Program 17 The Divisions Cardiology 20 Clinical Care Research 36 Clinical Decision Making 38 Clinical Nutrition 42 Endocrinology, Diabetes and Metabolism 46 Gastroenterology 54 Geographic Medicine and Infectious Diseases 60 Hematology/Oncology 70 Internal Medicine and Adult Primary Care 84 Geriatrics 92 William B. Schwartz Division of Nephrology 94 Palliative Care 104 Pulmonary, Critical Care and Sleep Medicine 108 Rheumatology, Allergy and Immunology 118 The Institutes Institute for Clinical Research and Health Policy Studies 130 Molecular Cardiology Research Institute (MCRI) 142 Publications 152 3 CHAIRMAN’S MESSAGE 2018 saw a major leadership change at Tufts Medical Center. The longtime CEO, Michael Wagner, MD, transitioned to the Chief Physician Executive and eventually Interim » CHAIRMANS CEO role at our parent corporation, Wellforce, which has grown recently with the addition of several new hospitals. During the national (and, as it turned out, MESSAGE international) search for a new CEO, I was asked to serve as interim co-CEO of the Deeb N. Salem, MD, FACP, FACC, FACCP— The Sheldon M. Wolff Professor and medical center for several months. It was a truly gratifying experience, but I was Chairman, Department of Medicine also very happy to return to my regular role in the department of medicine. In November, Dr. Michael Apkon, an accomplished physician and leader who was CEO of the Toronto Children’s Hospital, was named CEO of Tufts Medical Center. In the Department of Cardiology and the affiliated Center for Cardiovascular Research, there was continued high volume and outstanding outcomes in cardiac transplantation and ventricular assist devices. Tufts Medical Center also enjoyed the highest volume in the world of new patient referrals for hypertrophic cardiomyopathy, as well as a growing volume of myomectomies and surgical ablations. The transcatheter aortic valve replacement program grew and the Watchman left atrial occlusion device program was initiated. The expertise of the Division of Clinical Decision-Making was recognized by the membership of its Chief, Dr. John Wong, on multiple prestigious panels to evaluate the utility of various disease-preventive measures, cardiac imaging procedures and liver disease. The Division of Endocrinology, Diabetes and Metabolism continued its landmark NIH-supported studies of the effects of vitamin D supplementation on the risk of diabetes, cancer and cardiovascular disease and on muscle performance in older adults. Under the leadership of the Division of Geographic Medicine and Infectious Diseases, the Antimicrobial Stewardship Program was initiated and was one of 20 institutions given an Antimicrobial Stewardship Center of Excellence Award by the CDC. For her leadership in this effort, Dr. Gabriela Andujar was recognized by an award from the IDSA and CDC. Tufts University School of Medicine and Tufts Medical Center jointly founded the Center for the integrated Management of Antimicrobial Resistance under the leadership of Helen Boucher, MD and Ralph Isberg, PhD. Dr. Rachel Buchsbaum was named the Dr. Jane DesForges Chair in Hematology/ Oncology and became the new chief of the division. TUFTS MEDICAL CENTER DEPARTMENT OF MEDICINE — ANNUAL REPORT 2018 The Division of Internal Medicine and Adult Primary Care added a new primary care physician, 3 new Physician’s Assistants, 2 community health workers, and 2 case managers to the academic medical center practice. Members of the William B. Schwartz Division of Nephrology received teaching awards from the National Kidney Foundation, the Massachusetts Medical Society, Tufts Medical Center house staff and fellows and from the medical school. A new faculty member joined the Division of Palliative Care, expanding its ability to care for patients with serious illnesses. In the Division of Pulmonary, Critical Care and Sleep Medicine, Dr. Nick Hill chaired the search committee for a new Executive Director of the American Thoracic Society. Eric Garpestad was appointed Associate Chief Medical Officer in addition to his role as Associate Chief of the division. Several clinical faculty joined the division. In the Division of Rheumatology, Allergy and Immunology, five members received the Boston Magazine’s ‘Top Doctors” award. Dr. Timothy McAlindon received a prestigious Distinguished Clinical Research Award from the Clinical Research Foundation. Dr. Chenchen Wang received the 2020 Innovative Research Award from the American College of Rheumatology. Dr. Michelle Park received the Outstanding Young Investigator Award at the 2018 NIH International Congress on Integrative Medicine. Although the two institutes are not formally a part of Tufts Medical Center, there is great overlap between members of the institutes and members of clinical divisions, fostering useful collaborations between current clinical needs and basic research. The Molecular Cardiology Research Institute (MCRI) celebrated its twentieth anniversary and its chief, Iris Jaffe, was elected to the Association of University Cardiologists. The Institute for Clinical Research and Health Policy Studies (ICRHPS) received over $7 million in new funding for research projects and currently is overseeing 80 research projects; Its CTSA Award from the NIH was renewed with grant awards of $56 million. I am grateful to these clinician, teachers, administrators, and investigators, who, once more, have demonstrated their commitment and talent to further the missions of Tufts Medical Center. Sincerely yours, Deeb Salem 5 DIVERSITY AND INCLUSION EFFORTS WITHIN THE DEPARTMENT OF MEDICINE–2018-19 The Department through its administrative activities and the faculty within the Department are involved in a number of activities in promote diversity and inclusion efforts within the Department. 1. Efforts to change the culture of inclusion active in the new PO Diversity Committee and their The Department’s annual review form asks each efforts to increase and retain a diverse faculty. » DIVERSITY AND faculty member to reflect on his or her contribution to 5. Expansion of research on health disparities a culture of inclusion and diversity. This addition to The Program on Equity in Science and Health, led by the annual review form was intended to emphasize Dr. Freund, currently has two NIH research grants and diversity and inclusion as a core value within the several training grants addressing health disparities Department. Faculty reflect upon their role in the care INCLUSION research. These activities have attracted a number of of an increasingly diverse patient population. Many new URM trainees, and resulted in new collaborations are in a position to expand on the training efforts with URM faculty from other Tufts Institutes and across the spectrum of trainees. Schools. 2. Efforts at the Student level 6. Faculty Training Faculty report a number of activities to increase and The Department of Medicine will embark in this year support diversity in our students and trainees, on a R25 funded faculty development program, including participation on the TUSM admissions entitled BRIM – Bias Reduction in Internal Medicine. committee, and serving as mentors to URM medical This program is part of an educational trial to students and high school students as part of pipeline understand the impact of two different models of programs. faculty training on reduction bias, and its impact on 3. Efforts at the resident/fellowship level both attitudes and actions toward inclusion behavior. Our residency program and fellowship programs are The Department has in addition worked to offer this developing specific outreach activities in conjunction training across all TUSM faculty on the Boston with the Dean for Multicultural Affairs to increase the campus, both at Tufts Medical Center, and in the diversity of their applicant pool. We are tracking our TUSM employed faculty in the basic science divisions recruitment efforts including the number of URM and community medicine and public health to benefit trainees invited for interviews, those we rank to join from this training opportunity. Dr. Freund was us , and those who rank us sufficiently highly to match awarded a TUSM IDEAS innovation grant to with our programs. implement this training. 4. Efforts at the faculty level Women in Medicine Committee – The Department provided the initial support to the formation of this committee, which is now a TMC-wide committee, to promote the career advancement of women within the Department
Recommended publications
  • Emergency Behavioral Health Services

    Emergency Behavioral Health Services

    ALERT #24 ___________________ October 5, 2007 EMERGENCY BEHAVIORAL HEALTH SERVICES POLICIES AND PROCEDURES FOR EMERGENCY SERVICES PROGRAMS AND HOSPITAL EMERGENCY DEPARTMENTS FOR MBHP MEMBERS AND UNINSURED CONSUMERS The following information should be communicated immediately to other appropriate staff in your organization. The Massachusetts Behavioral Health Partnership (MBHP) is the company that manages behavioral health (mental health and substance abuse) services for MassHealth’s Primary Care Clinician (PCC) Plan Members*. Additionally, MBHP is contracted with the Department of Mental Health to manage most of the Emergency Services Programs (ESPs) across the Commonwealth. In that role, MBHP is issuing this Alert to hospital Emergency Departments (EDs), MBHP network providers, and other interested stakeholders in order to provide clarification and guidance relative to the management of behavioral health emergencies in the ED setting. More specifically, this Alert delineates the roles and responsibilities of the Emergency Services Programs (ESPs) and describes an individual’s progression through this system, with a goal of expediting his or her movement through the hospital ED and into acute behavioral health services, as medically necessary. ESPs function as a “safety net” for all citizens of the Commonwealth regardless of age, payer, or ability to pay. It is important to note that the policies and procedures in this Alert applies to those populations for whom the ESPs are contracted with MBHP to serve, which includes MBHP members, MassHealth (non-MCO enrolled) Members, uninsured consumers, and DMH consumers. However, it is also important to note that MassHealth also requires the four Managed Care Organizations (MCOs) contracted with MassHealth to utilize the ESP system for emergency behavioral health services for MassHealth MCO enrolled Members.
  • Community Choice Acute Care Hospital Listing Effective July 1, 2017 When You Use a Community Choice Hospital, You Pay a $275 Inpatient Copay Per Calendar Quarter

    Community Choice Acute Care Hospital Listing Effective July 1, 2017 When You Use a Community Choice Hospital, You Pay a $275 Inpatient Copay Per Calendar Quarter

    UNICARE STATE INDEMNITY PLAN Community Choice Acute Care Hospital Listing Effective July 1, 2017 When you use a Community Choice hospital, you pay a $275 inpatient copay per calendar quarter. Community Choice members can also use additional hospitals for the same $275 copay for certain complex procedures and neonatal ICUs. To look for hospitals, go to unicarestateplan.com and, under the Quick Links tab on the Members page, select Look for health care providers. When you use non-Community Choice hospitals, your out-of-pocket costs are higher. Addison Gilbert Hospital Lawrence Memorial Hospital Anna Jaques Hospital Leominster Hospital (UMass Memorial) Athol Memorial Hospital Leonard Morse Hospital Baystate Franklin Medical Center Lowell General Hospital Baystate Medical Center Mary Lane Hospital (Baystate) Berkshire Medical Center Massachusetts Eye and Ear Beth Israel Deaconess Medical Center – Boston Melrose-Wakefield Hospital Beverly Hospital Mercy Medical Center Brockton Hospital Merrimack Valley Hospital Burbank Hospital (UMass Memorial) Milford Regional Medical Center Cambridge Hospital Milton Hospital (Beth Israel Deaconess) Cape Cod Hospital Morton Hospital Carney Hospital Mount Auburn Hospital Charlton Memorial Hospital Nashoba Valley Medical Center Children’s Hospital Boston Needham Hospital (Beth Israel Deaconess) Cooley Dickinson Hospital New England Baptist Hospital *Dana-Farber Cancer Institute (Boston location only) Noble Hospital (Baystate) Emerson Hospital Norwood Hospital Everett Hospital (formerly Whidden Hospital) Plymouth
  • Recent Advances in Drug Discovery of GPCR Allosteric Modulators

    Recent Advances in Drug Discovery of GPCR Allosteric Modulators

    Recent Advances in Drug Discovery of GPCR Allosteric Modulators ADDEX Pharma S.A., Head of Core Chemistry Chemin Des Aulx 12, 1228 Plan-les-Ouates, Geneva, Switzerland Jean-Philippe Rocher, PhD results in a number of differentiating factors. In fact, most Introduction allosteric modulators have little or no effect on receptor function until the active site is bound by an orthosteric The importance of the allosteric regulation of cellular ligand. Allosteric modulators therefore have multiple functions has been known for decades and even the word potential advantages compared to small molecule and “allosterome,” which describes the endogenous alloste- biologic orthosteric drugs. In particular, they offer new ric regulator molecules of a cell, has been proposed 1. chemistry possibilities allowing access to well known tar- Although best described as modulators of enzymes, gets that have been considered intractable to historical advances in molecular biology and robotic HTS technolo- small molecule approaches. For example, allosteric mod- gies recently allowed the discovery of small molecule allo- ulators may soon be developed for targets which hereto- steric modulators of various biological systems, including fore have been only successfully targeted with proteins GPCR and non-GPCR targets. Today, allosteric modula- and peptides. In other words, allosteric drugs with all the tors appear to be an emerging class of orally available advantages of small molecules － brain penetration, eas- therapeutic agents that can offer a competitive advantage ier manufacturing, distribution and oral administration over classical “orthosteric” drugs. This potential stems - may soon be viewed as the best life cycle management from their ability to offer greater selectivity and differ- strategy for protein therapeutics 2.
  • Color Our Collections 2019

    Color Our Collections 2019

    COLOR OUR COLLECTIONS 2019 @HarvardHistMed #ColorOurCollections Enabling the history of medicine to inform contemporary medicine and society The Center for the History of Medicine enables the history of medicine to inform contemporary medicine and deepens our understanding of the society in which medicine is embedded. One of the world's leading resources for the study of the history of health and medicine, the Center attracts a global audience of researchers to its integrated collections of rare books, journals, archives, manuscripts, artifact collections, and visual, sound, and moving image works. Our public programs, exhibits, initiatives, and content curation activities are directed to a diverse audience of health professionals, students, academic researchers, and the general public and derive strength of purpose from the Harvard Medical School, Harvard School of Dental Medicine, Harvard T. H. Chan School of Public Health, Boston Medical Library, and Longwood Medical and Academic Area communities. Visit our online digital collections site, OnView (collections.countway.harvard.edu/onview/), to browse digital exhibits, documents, photographs, museum objects, and more. Visit our blog (cms.www.countway.harvard.edu/wp/) to learn about collections, events, and initiatives; and follow us on Twitter and Instagram: @HarvardHistMed. The Center for the History of Medicine is part of the Francis A. Countway Library of Medicine, a partnership of the Harvard Medical School and Boston Medical Library. Learn more at c ountway.harvard.edu. The Center for the History of Medicine, Francis A. Countway Library of Medicine, a partnership of the Harvard Medical School and Boston Medical Library #ColorOurCollections @HarvardHistMed Theatrum Chemicum Britannicum, 1652. Available via the Medical Heritage Library: https://archive.org/details/theatrumchemicum00ashm/page/n6 The Center for the History of Medicine, Francis A.
  • Harvard Library Bulletin, Volume 6.2)

    Harvard Library Bulletin, Volume 6.2)

    Harvard Library bibliography: Supplement (Harvard Library Bulletin, Volume 6.2) The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Carpenter, Kenneth E. 1996. Harvard Library bibliography: Supplement (Harvard Library Bulletin, Volume 6.2). Harvard Library Bulletin 6 (2), Summer 1995: 57-64. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:42665395 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA 57 Harvard Library Bibliography: Supplement his is a list of selected new books and articles of which any unit of the Harvard T University Library is the author, primary editor, publisher, or subject. The list also includes scholarly and professional publications by Library staff. The bibli- ography for 1960-1966 appeared in the Harvard Library Bulletin, 15 (1967), and supplements have appeared in the years following, most recently in Vol. 3 (New Series), No. 4 (Winter 1992-1993). The list below covers publications through mid-1995. Alligood, Elaine. "The Francis A. Countway Library of Medicine: Poised for the Future, Guided by the Past," in Network News, the quarterly publication of the Massachu- setts Health Sciences Library Network (August 1994). (Elaine Alligood was formerly Assistant Director for Marketing in the Countway Library of Medicine.) Altenberger, Alicja and John W. Collins III. "Methods oflnstruction in Management for Libraries and Information Centers" in New Trends in Education and Research in Librarianshipand InformationScience (Poland:Jagiellonian University, 1993), ed.
  • Wayfair Preferred (Narrow) Network Plan Hospitals

    Wayfair Preferred (Narrow) Network Plan Hospitals

    Wayfair Preferred (Narrow) Network Hospitals Hospital Name City State Addison Gilbert Hospital Gloucester MA Anna Jaques Hospital Newburyport MA BayRidge Hospital (acute psychiatric hospital) Lynn MA Beth Israel Deaconess Medical Center—Boston Boston MA Beth Israel Deaconess Hospital—Milton Milton MA Beth Israel Deaconess Hospital—Needham Campus Needham MA Beth Israel Deaconess Hospital—Plymouth Plymouth MA Beverly Hospital Beverly MA Boston Children’s Hospital Boston MA Boston Medical Center Boston MA Brigham and Women’s/Mass General Health Care Center at Patriot Place Foxborough MA Cambridge Health Alliance—Cambridge Campus Cambridge MA Cambridge Health Alliance—Somerville Campus Somerville MA Cambridge Health Alliance—Whidden Campus Everett MA Carney Hospital Dorchester MA Clinton Hospital Clinton MA Cooley Dickinson Hospital Northampton MA Emerson Hospital Concord MA Faulkner Hospital Jamaica Plain MA Good Samaritan Medical Center Brockton MA HealthAlliance Hospitals—Burbank Campus Fitchburg MA HealthAlliance Hospitals—Leominster Campus Leominster MA Heywood Hospital Gardner MA Holyoke Medical Center Holyoke MA Lahey Hospital and Medical Center Burlington MA Hospital Name City State Lahey Medical Center Peabody MA Lawrence General Hospital Lawrence MA Lawrence Memorial Hospital Medford MA Lowell General Hospital (includes the campus Lowell MA formerly known as Saints Medical Center) Massachusetts Eye and Ear®´ Infirmary Boston MA Mass General/North Shore Center for Outpatient Care Danvers MA Melrose-Wakefield Hospital Melrose MA Mercy
  • Biased Signaling of G Protein Coupled Receptors (Gpcrs): Molecular Determinants of GPCR/Transducer Selectivity and Therapeutic Potential

    Biased Signaling of G Protein Coupled Receptors (Gpcrs): Molecular Determinants of GPCR/Transducer Selectivity and Therapeutic Potential

    Pharmacology & Therapeutics 200 (2019) 148–178 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Biased signaling of G protein coupled receptors (GPCRs): Molecular determinants of GPCR/transducer selectivity and therapeutic potential Mohammad Seyedabadi a,b, Mohammad Hossein Ghahremani c, Paul R. Albert d,⁎ a Department of Pharmacology, School of Medicine, Bushehr University of Medical Sciences, Iran b Education Development Center, Bushehr University of Medical Sciences, Iran c Department of Toxicology–Pharmacology, School of Pharmacy, Tehran University of Medical Sciences, Iran d Ottawa Hospital Research Institute, Neuroscience, University of Ottawa, Canada article info abstract Available online 8 May 2019 G protein coupled receptors (GPCRs) convey signals across membranes via interaction with G proteins. Origi- nally, an individual GPCR was thought to signal through one G protein family, comprising cognate G proteins Keywords: that mediate canonical receptor signaling. However, several deviations from canonical signaling pathways for GPCR GPCRs have been described. It is now clear that GPCRs can engage with multiple G proteins and the line between Gprotein cognate and non-cognate signaling is increasingly blurred. Furthermore, GPCRs couple to non-G protein trans- β-arrestin ducers, including β-arrestins or other scaffold proteins, to initiate additional signaling cascades. Selectivity Biased Signaling Receptor/transducer selectivity is dictated by agonist-induced receptor conformations as well as by collateral fac- Therapeutic Potential tors. In particular, ligands stabilize distinct receptor conformations to preferentially activate certain pathways, designated ‘biased signaling’. In this regard, receptor sequence alignment and mutagenesis have helped to iden- tify key receptor domains for receptor/transducer specificity.
  • Cell Penetrating Peptides, Novel Vectors for Gene Therapy

    Cell Penetrating Peptides, Novel Vectors for Gene Therapy

    pharmaceutics Review Cell Penetrating Peptides, Novel Vectors for Gene Therapy Rebecca E. Taylor 1 and Maliha Zahid 2,* 1 Mechanical Engineering, Biomedical Engineering and Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA 15213, USA; [email protected] 2 Department of Developmental Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15201, USA * Correspondence: [email protected]; Tel.: +1-412-692-8893; Fax: +1-412-692-6184 Received: 5 February 2020; Accepted: 1 March 2020; Published: 3 March 2020 Abstract: Cell penetrating peptides (CPPs), also known as protein transduction domains (PTDs), first identified ~25 years ago, are small, 6–30 amino acid long, synthetic, or naturally occurring peptides, able to carry variety of cargoes across the cellular membranes in an intact, functional form. Since their initial description and characterization, the field of cell penetrating peptides as vectors has exploded. The cargoes they can deliver range from other small peptides, full-length proteins, nucleic acids including RNA and DNA, liposomes, nanoparticles, and viral particles as well as radioisotopes and other fluorescent probes for imaging purposes. In this review, we will focus briefly on their history, classification system, and mechanism of transduction followed by a summary of the existing literature on use of CPPs as gene delivery vectors either in the form of modified viruses, plasmid DNA, small interfering RNA, oligonucleotides, full-length genes, DNA origami or peptide nucleic acids. Keywords: cell penetrating peptides; protein transduction domains; gene therapy; small interfering RNA 1. Introduction The plasma membrane of a cell is essential to its identity and survival, but at the same time presents a barrier to intracellular delivery of potentially diagnostic or therapeutic cargoes.
  • Equity Research

    Equity Research

    Equity Research Telco Friday,07 February 2020 Telco OVERWEIGHT Maintain Telco price tracker Jan 2020 TLKM relative to JCI Index Telkomsel’s (TSEL) recent products suggest potential change in market dynamics. In response, XL remains defensive, while we are seeing some xxxx positive indications further at the lower end, and thus maintain our overweight sector call. We introduce our telco scorecard to track price effects and network changes, with TLKM and EXCL having the most network leverage. A different ballgame with By.U. Growth in traffic vols continue to be sizeable as TSEL and XL Axiata reported traffic growth of ~+39%/38%yoy respectively, and Indosat at about +61%yoy during the festive period in Dec-Jan according to news reports. TSEL’s core data offerings have not been altered since 4Q19 as TSEL would want to evaluate the traction effects from “OMG!” and the new product line “By.U”. While OMG! does enrich TSEL’s portfolio with SoSMed and content, By.U by contrast seeks to get more traffic with effective GB yields to levels below Rp4,300. By.U is designed to be set apart from TSEL’s branding to pursue millennials and student groups. While there is time to tweak prices further before the next Lebaran season in 2020, By.U is potentially disruptive EXCL relative to JCI Index putting pressure on contenders’ value chains. xxxx XL rewards existing users with discounts. Our channel check reveals that XL itself offered discounts in the 8-13% range on flagship products for existing users, while a new XL prepaid user can choose a service only based on nominal prices.
  • 1 Advances in Therapeutic Peptides Targeting G Protein-Coupled

    1 Advances in Therapeutic Peptides Targeting G Protein-Coupled

    Advances in therapeutic peptides targeting G protein-coupled receptors Anthony P. Davenport1Ϯ Conor C.G. Scully2Ϯ, Chris de Graaf2, Alastair J. H. Brown2 and Janet J. Maguire1 1Experimental Medicine and Immunotherapeutics, Addenbrooke’s Hospital, University of Cambridge, CB2 0QQ, UK 2Sosei Heptares, Granta Park, Cambridge, CB21 6DG, UK. Ϯ Contributed equally Correspondence to Anthony P. Davenport email: [email protected] Abstract Dysregulation of peptide-activated pathways causes a range of diseases, fostering the discovery and clinical development of peptide drugs. Many endogenous peptides activate G protein-coupled receptors (GPCRs) — nearly fifty GPCR peptide drugs have been approved to date, most of them for metabolic disease or oncology, and more than 10 potentially first- in-class peptide therapeutics are in the pipeline. The majority of existing peptide therapeutics are agonists, which reflects the currently dominant strategy of modifying the endogenous peptide sequence of ligands for peptide-binding GPCRs. Increasingly, novel strategies are being employed to develop both agonists and antagonists, and both to introduce chemical novelty and improve drug-like properties. Pharmacodynamic improvements are evolving to bias ligands to activate specific downstream signalling pathways in order to optimise efficacy and reduce side effects. In pharmacokinetics, modifications that increase plasma-half life have been revolutionary. Here, we discuss the current status of peptide drugs targeting GPCRs, with a focus on evolving strategies to improve pharmacokinetic and pharmacodynamic properties. Introduction G protein-coupled receptors (GPCRs) mediate a wide range of signalling processes and are targeted by one third of drugs in clinical use1. Although most GPCR-targeting therapeutics are small molecules2, the endogenous ligands for many GPCRs are peptides (comprising 50 or fewer amino acids), which suggests that this class of molecule could be therapeutically useful.
  • Boston a Guide Book to the City and Vicinity

    Boston a Guide Book to the City and Vicinity

    1928 Tufts College Library GIFT OF ALUMNI BOSTON A GUIDE BOOK TO THE CITY AND VICINITY BY EDWIN M. BACON REVISED BY LeROY PHILLIPS GINN AND COMPANY BOSTON • NEW YORK • CHICAGO • LONDON ATLANTA • DALLAS • COLUMBUS • SAN FRANCISCO COPYRIGHT, 1928, BY GINN AND COMPANY ALL RIGHTS RESERVED PRINTED IN THE UNITED STATES OF AMERICA 328.1 (Cfte gtftengum ^regg GINN AND COMPANY • PRO- PRIETORS . BOSTON • U.S.A. CONTENTS PAGE PAGE Introductory vii Brookline, Newton, and The Way about Town ... vii Wellesley 122 Watertown and Waltham . "123 1. Modern Boston i Milton, the Blue Hills, Historical Sketch i Quincy, and Dedham . 124 Boston Proper 2 Winthrop and Revere . 127 1. The Central District . 4 Chelsea and Everett ... 127 2. The North End .... 57 Somerville, Medford, and 3. The Charlestown District 68 Winchester 128 4. The West End 71 5. The Back Bay District . 78 III. Public Parks 130 6. The Park Square District Metropolitan System . 130 and the South End . loi Boston City System ... 132 7. The Outlying Districts . 103 IV. Day Trips from Boston . 134 East Boston 103 Lexington and Concord . 134 South Boston .... 103 Boston Harbor and Massa- Roxbury District ... 105 chusetts Bay 139 West Roxbury District 105 The North Shore 141 Dorchester District . 107 The South Shore 143 Brighton District. 107 Park District . Hyde 107 Motor Sight-Seeing Trips . 146 n. The Metropolitan Region 108 Important Points of Interest 147 Cambridge and Harvard . 108 Index 153 MAPS PAGE PAGE Back Bay District, Showing Copley Square and Vicinity . 86 Connections with Down-Town Cambridge in the Vicinity of Boston vii Harvard University ...
  • Manager and Executive Compensation in Hospitals and Health Systems Survey Report

    Manager and Executive Compensation in Hospitals and Health Systems Survey Report

    2019 Manager and Executive Compensation in Hospitals and Health Systems Survey Report Survey data effective January 1, 2019 © 2019 SullivanCotter, Inc. All rights reserved. 200 W. Madison Street, Suite 2450 Chicago, IL 60606-3416 2019 MANAGER AND EXECUTIVE COMPENSATION IN HOSPITALS AND HEALTH SYSTEMS SURVEY REPORT Survey data effective January 1, 2019 LICENSE AGREEMENT LICENSE AGREEMENT By accessing or downloading the Survey Report files online or by opening the packaging for this Survey Report, you agree to the terms of this License Agreement (this “Agreement”). If you do not agree to these terms and have not yet accessed or downloaded the Survey Report files or opened the packaging for this Survey Report, you may cancel your online purchase or download at this time or you may return this Survey Report to SullivanCotter, Inc. for a full refund within thirty (30) days of receipt, but you may not access or download the Survey Report files or open the packaging for, or otherwise use, this Survey Report. Accessing or downloading the Survey Report files or opening the packaging, or otherwise using, this Survey Report binds you to this Agreement. This Agreement is entered into by and between SullivanCotter, Inc. ("SullivanCotter") and the purchaser or participant of this Survey Report (the “Licensee”). In consideration of the mutual covenants in this Agreement, SullivanCotter and the Licensee agree as follows: Grant of License. This Survey Report contains the aggregation of compensation data and other data provided to SullivanCotter by its survey participants, statistics, tables, reports, research, aggregations, calculations, data analysis, formulas, summaries, content, text and other information and materials provided to the Licensee by SullivanCotter through any other means, whether digital or hard copy, related thereto (the “Aggregated Data”).